# About Online CJC-1295: An Independent Research Digest

> Online CJC-1295 is an independent editorial digest of the peer-reviewed CJC-1295 research. Not a clinic, not a vendor — a cited reading of the published record.

What this site is, what it is not, and how it handles the record.

## What Online CJC-1295 is

Online CJC-1295 is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The site reads the published CJC-1295 record — the GH/IGF-1 axis pharmacokinetics, the DAC albumin-conjugation chemistry, the animal proof-of-concept, and the regulatory status — and lays it out as a curated board: landmark findings sized as featured tiles, supporting identifiers in smaller cells, and the honest gaps marked plainly. Every quantitative claim is tied to a numbered citation that resolves to a real study on the references page.

## What the name means

The "online" in the name is editorial framing — a position this publisher occupies relative to the literature, a place to read the research, not a storefront and not a checkout. We do not sell CJC-1295, we do not source it, and we do not point readers to anyone who does. The word describes a reading surface for an accessible, plain-language digest of what the published research shows; it is not a claim about products or services.

This distinction matters because much of what is written about CJC-1295 online is promotional. This site is the opposite: it reports what specific studies measured, names where the human data stop, and keeps the DAC and no-DAC forms carefully apart, since conflating them is the most common error in the popular coverage.

## How we handle the record

We lead with the finding and attribute it to the study that produced it. Where the evidence is strong — the 5.8-8.1 day DAC half-life, the multi-day GH and IGF-1 elevation, the preserved pulsatility — we say so plainly. Where it is thin — no large efficacy trial, no long-term safety data, no validated human dose, a discontinued development program — we say that just as plainly, and we mark it on the page rather than burying it.

CJC-1295 is not approved for human use, and nothing on this site is a dosing recommendation or a course of treatment. Doses and routes are reported as research context: what was administered, to which species, by which route, in which study. The goal is a reader who finishes knowing what the literature genuinely establishes about the GH/IGF-1 axis and where it falls silent.

---

A curated night-board of the CJC-1295 record — each study, kinetic figure, and honest gap lit in its own tile and weighed by what the literature can actually carry, with no clinic behind the board and nothing here dispensed or sold.